You have read all your free articles, to continue reading subscribe to read the rest of this content.
Novo Nordisk has announced the decision to enter phase 3 development in Alzheimer’s disease with 14 mg oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analogue semaglutide. The decision follows evaluation of GLP-1 data from preclinical models, real-world evidence studieAlready a subscriber Login You have read all your…
Nordic Nanovector announces initial promising data from the Archer-1 Phase 1b trial investigating Betalutin (177Lu lilotomab satetraxetan) in combination with rituximab (RTX) in second-line follicular lymphoma (2L FL). The preliminary results show clinical activity with seven out of seven patientAlready a subscriber Login You have read all your free articles,…
The European Medicines Agency (EMA) is now inviting companies to participate in its adaptive licensing pilot project. Any company who is interested in participating in the pilot are requested to submit ongoing medicine development programmes for consideration as prospective pilot cases, states thAlready a subscriber Login You have read all…
A multi-center open label Phase 1b trial of BerGenBio AS’s BGB324, a selective inhibitor of Axl, in patients with Stage IIIb and Stage IV non-small cell lung cancer in erlotinib-sensitive and refractory patients who have an activating EGFR mutation, is now underway. The study is conducted at the UAlready a…
